Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pioglitazone: more than just an insulin sensitizer.

Literature DB >> 19402055

Pioglitazone: more than just an insulin sensitizer.

Mark J Czaja.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19402055 PMCID： PMC2689873 DOI： 10.1002/hep.22983

Source DB: PubMed Journal: Hepatology ISSN： 0270-9139 Impact factor: 17.425

× No keyword cloud information.

23 in total

1. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.

Authors: Guenther Boden; Carol Homko; Maria Mozzoli; Louise C Showe; Calen Nichols; Peter Cheung
Journal: Diabetes Date: 2005-03 Impact factor: 9.461

Review 2. The mechanisms of action of PPARs.

Authors: Joel Berger; David E Moller
Journal: Annu Rev Med Date: 2002 Impact factor: 13.739

3. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice.

Authors: Eyal Shteyer; Yunjun Liao; Louis J Muglia; Paul W Hruz; David A Rudnick
Journal: Hepatology Date: 2004-12 Impact factor: 17.425

4. Insulin hyperresponsiveness in partially hepatectomized diabetic rats.

Authors: M C Carrillo; C Favre; J A Monti; M L Alvarez; C E Carnovale
Journal: Life Sci Date: 2001-02-09 Impact factor: 5.037

5. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology.

Authors: S Q Yang; H Z Lin; A K Mandal; J Huang; A M Diehl
Journal: Hepatology Date: 2001-10 Impact factor: 17.425

6. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha.

Authors: Robert A DeAngelis; Maciej M Markiewski; Rebecca Taub; John D Lambris
Journal: Hepatology Date: 2005-11 Impact factor: 17.425

7. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.

Authors: Tomonori Aoyama; Kenichi Ikejima; Kazuyoshi Kon; Kyoko Okumura; Kumiko Arai; Sumio Watanabe
Journal: Hepatology Date: 2009-05 Impact factor: 17.425

Review 8. Nonalcoholic fatty liver disease and liver transplantation.

Authors: Paul Angulo
Journal: Liver Transpl Date: 2006-04 Impact factor: 5.799

9. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal: Nat Med Date: 2001-08 Impact factor: 53.440

10. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440

5 in total

1. Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.

Authors: Oelfah Patel; Christo J F Muller; Elizabeth Joubert; Bernd Rosenkranz; Johan Louw; Charles Awortwe
Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240

2. Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis.

Authors: Pi-Jung Hsiao; Hsin-Ying Clair Chiou; He-Jiun Jiang; Mei-Yueh Lee; Tusty-Jiuan Hsieh; Kung-Kai Kuo
Journal: Sci Rep Date: 2017-08-22 Impact factor: 4.379

Review 3. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Authors: Stefano Del Prato; Robert Chilton
Journal: Diabetes Obes Metab Date: 2017-12-21 Impact factor: 6.577

4. A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease.

Authors: Theodore R Rieger; Richard J Allen; Cynthia J Musante
Journal: Front Pharmacol Date: 2022-07-19 Impact factor: 5.988

Review 5. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors: Anne Fougerat; Alexandra Montagner; Nicolas Loiseau; Hervé Guillou; Walter Wahli
Journal: Cells Date: 2020-07-08 Impact factor: 6.600

5 in total